Clinical trial · Observational
Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer
Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer: An Observational Study
NCT06783127CI-TRIAL-00085762COROSrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is an observational, retrospective/prospective, multicenter study designed to define, overall survival, clinical outcomes and predictive/prognostic factors of a consecutive population of mCRPC patients treated with olaparib in clinical practice.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| BRCA Mutation | — | UNRESOLVED | — |
| Castrate Resistant Prostate Cancer | — | UNRESOLVED | — |
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Olaparib | Drug | Olaparib | ALIAS |
Design
Arms and outcomes
Arms (1)
- label
- mCRPC treated with olaparib
- description
- mCRPC patients who receive olaparib in daily clinical practice
- interventionNames
- Drug: Olaparib
Primary outcomes (1)
- measure
- disease control
- timeFrame
- From the date of treatment start until the date of last follow-up or date of death from any cause, whichever came first, assessed up to 120 months
- description
- projected survival from treatment start
Secondary outcomes (4)
- measure
- biochemical response
- timeFrame
- Through study completion, an average of 1 years
- description
- rate of patients with PSA reduction \> 50%
Eligibility
Eligibility (as posted)
- Sex
- Male
Show eligibility criteria text
Inclusion Criteria: BRCA mutant Metastatic castration-resistant prostate cancer patients treatment with olaparib in clinical practice Exclusion Criteria: Olaparib treatment in a clinical trial
References
Publications (0)
Data not yet available
No reference posted for this study.